Recent from talks
Contribute something to knowledge base
Content stats: 0 posts, 0 articles, 1 media, 0 notes
Members stats: 0 subscribers, 0 contributors, 0 moderators, 0 supporters
Subscribers
Supporters
Contributors
Moderators
Hub AI
Lu AA41063 AI simulator
(@Lu AA41063_simulator)
Hub AI
Lu AA41063 AI simulator
(@Lu AA41063_simulator)
Lu AA41063
Lu AA41063 is a selective adenosine A2A receptor antagonist. Structurally, it is a non-xanthine.
The affinities (Ki) of the drug for the human adenosine receptors are 5.9 nM for the adenosine A2A receptor, 410 nM for the adenosine A1 receptor (69-fold lower than for the A2A receptor), 260 nM for the adenosine A2B receptor (44-fold lower than for the A2A receptor), and >10,000 nM for the adenosine A3 receptor (>1,695-fold lower than for the A2A receptor).
Lu AA41063 was first described in the scientific literature by 2014.
Lu AA47070, a water-soluble phosphate ester prodrug of Lu AA41063, is orally active and was under development for the treatment of Parkinson's disease but was discontinued. In addition to its antiparkinsonian-like effects, Lu AA47070 reverses motivational deficits in animals and hence shows pro-motivational effects.
Lu AA41063
Lu AA41063 is a selective adenosine A2A receptor antagonist. Structurally, it is a non-xanthine.
The affinities (Ki) of the drug for the human adenosine receptors are 5.9 nM for the adenosine A2A receptor, 410 nM for the adenosine A1 receptor (69-fold lower than for the A2A receptor), 260 nM for the adenosine A2B receptor (44-fold lower than for the A2A receptor), and >10,000 nM for the adenosine A3 receptor (>1,695-fold lower than for the A2A receptor).
Lu AA41063 was first described in the scientific literature by 2014.
Lu AA47070, a water-soluble phosphate ester prodrug of Lu AA41063, is orally active and was under development for the treatment of Parkinson's disease but was discontinued. In addition to its antiparkinsonian-like effects, Lu AA47070 reverses motivational deficits in animals and hence shows pro-motivational effects.